What is PhaseV?
PhaseV is at the forefront of revolutionizing clinical trial design and execution. The company leverages advanced algorithms, including reinforcement learning and causal machine learning, to create adaptive trial designs and enable closed-loop execution. This sophisticated methodology aims to significantly improve trial success rates while concurrently maximizing resource and time efficiency. PhaseV's novel technology is also instrumental in uncovering hidden data signals, facilitating deeper analysis of clinical trial results, and extracting actionable insights, positioning it as a key player in the health-tech and biotech sectors.
How much funding has PhaseV raised?
PhaseV has raised a total of $65M across 2 funding rounds:
Other Financing Round
$15M
Series A
$50M
Other Financing Round (2023): $15M with participation from LionBird, Viola Ventures, and Exor Ventures
Series A (2025): $50M led by Accel, Insight Partners, Viola Ventures, EXOR, and LionBird
Key Investors in PhaseV
LionBird
LionBird (Ventures) Ltd. is a venture capital firm specializing in innovative health-tech startups that aim to transform the healthcare landscape through technology. They provide pre-scale capital and support to teams dedicated to improving healthcare solutions.
Viola Ventures
Viola Ventures is an assisted living community company dedicated to providing personalized care to residents in Eastern North Carolina, operating several facilities focused on creating a supportive environment for seniors.
Exor Ventures
Exor Ventures is a venture capital and private equity firm headquartered in Ireland, focusing on investments within the Information & Document Management industry.
What's next for PhaseV?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for PhaseV. This capital infusion is expected to accelerate the company's product development, expand its market reach, and further enhance its technological capabilities. Investors are likely backing PhaseV's vision to transform the efficiency and effectiveness of clinical research, suggesting a strategic focus on scaling operations and solidifying its position as a leader in adaptive trial design and data analytics within the pharmaceutical and biotechnology industries.
See full PhaseV company page
